Shin Hatou, one of the founder’s of Cellusion, began research on corneal endothelium regenerative medicine

Core technology patent filed to create corneal endothelial cells from induced pluripotent stem (iPS) cells via neural crest cells

Prof. Kazuo Tsubota, Prof. Shigeto Shimmura, and Prof. Shin Hatou of the Department of Ophthalmology, Keio University School of Medicine, founded Cellusion Inc. in Setagaya-ku, Tokyo, with Shin Hatou appointed as CEO

Core technology patent filed to create corneal endothelial substitute cells directly from iPS cells

Selected for NEDO STS project 2019

Received JHVS2019 Venture Award

Certified as J-TECH STARTUP 2019
Cellusion Laboratory opened in Chuo-ku, Tokyo and headquarters was relocated to Chuo-ku, Tokyo
Received Series A financing
Established Board of Directors

Received additional Series A financing

Executed a capital reduction without compensation

"Corneal Endothelial Cell Substitute from iPS Cells Transplant Plan on Bullous Keratopathy Treatment (Research Code: CLS001)" approved by the Keio Specially Certified Committee for Regenerative Medicine

Clinical Study Plan on Corneal Endothelial Cell Substitute from iPS Cells Transplant Plan for Bullous Keratopathy Patient approved by the Japanese Ministry of Health, Labour and Welfare’s Health Science Council

Named winner of Boehringer Ingelheim Innovation Prize 2021

Received 1st Prize in JHVS2021 Global Pitch

Formed a capital and business alliance with Toho Holdings
Formed a capital and business alliance with Toyo Seikan Group Holdings
Received Series B financing

Received JHVS2021 Venture Award

Established Board of Corporate Auditors

Formed a business alliance with Nikon CeLL innovation for development and production of CLS001 for commercialization

Executed a capital reduction without compensation

Relocated headquarters to Nihonbashi-Kobunacho area

Entered into a license agreement with Celregen, a subsidiary of Fosun Pharma

Formed a business alliance with Minaris Regenerative Medicine, a subsidiary of Showa Denko Materials, to expand globally

Received JHVS2022 Venture Award

Selected for METI’s J-Startup support program

Received Series C financing

Received MEXT Minister’s Award in the Award for Academic Startups 2023

Executed a capital reduction without compensation

Cellusion CEO, Dr. Shin Hatou received the METI Minister’s Award at the 23rd Japan Venture Awards

Selected for AMED “Strengthening Program for Pharmaceutical Startup Ecosystem”

Relocated headquarters to Harumi, Chuo-ku, Tokyo and established own laboratory